Physician profile
Katie L Sutter
NPI 1043651128
$1,060.93
in general payments reported to CMS, 2019-2025
14 companies · $245 in 2025
The $245 reported for 2025 was more than what a typical Pediatrics (Optometrist) provider received nationally (typical 2025 total: $152).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $165 · 2020: $56.83 · 2021: $162 · 2022: $42.04 · 2023: $194 · 2024: $196 · 2025: $245.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $634.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $634.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $182.33 | 2023-2025 | Infuse, Biotrue One Day, Miebo |
| Alcon Vision LLC | $172.87 | 2020-2025 | Total30, Precision 7, Rocklatan |
| Sun Pharmaceutical Industries INC. | $160.64 | 2021-2025 | Cequa |
| Johnson & Johnson Vision Care, INC. | $128.01 | 2019-2025 | Acuvue |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $99.27 | 2019-2021 | |
| Coopervision INC. | $68.51 | 2019-2024 | Myday Contact Lens |
| Tarsus Pharmaceuticals, INC. | $60.48 | 2025 | Xdemvy |
| Kala Pharmaceuticals, INC. | $47.73 | 2021 | |
| Novartis Pharmaceuticals Corporation | $40.26 | 2019-2020 | |
| Horizon Therapeutics Plc | $26.51 | 2022-2023 | Tepezza |
| Dompe US, INC. | $22.52 | 2024 | Oxervate |
| Oyster Point Pharma, INC. | $19.24 | 2023 | Tyrvaya |
| Allergan, INC. | $17.99 | 2021 | |
| Biotissue Holdings INC. | $14.57 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katie Sutter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.